Global Gadolinium-based Contrast Agent Market: Snapshot
Gadolinium-based contrast agent (GBCA) also referred to as magnetic resonance imaging (MRI) contrast media or dyes are chemical substances that are used in magnetic resonance imaging based diagnostics. When administered into the body, gadolinium-based contrast agent enhances the quality of MRI scans. This allows an accurate analysis of how the body is working for diseases detection or any other abnormality.
Read Report Overview: https://www.transparencymarketresearch.com/gadolinium-based-contrast-agent-market.html
Gadolinium-based contrast agent comprise complex molecules that are held together by chemical bonds. The chemical bond is created between a gadolinium ion and a chelating agent. The use of chelating agents is not standard and is subjective to the gadolinium contrast medium brand. The contrast medium is administered into the body as part of the MRI scan, and is expelled from the body through the kidneys.
Gadolinium-based contrast agents are considered safe as contrast media for magnetic resonance imaging when used at recommended dosage. This is because GBCAs are completely extracted from the body in an intact state.
However, over the last decade, there is a growing body of data that indicates gadolinium accumulates in tissues of patients who are exposed to GBCAs for magnetic resonance imaging. Gadolinium retention is observed to be more in individuals who are repeatedly exposed to GBCA.
Download Brochure Copy of this Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22862
Gadolinium-based contrast agent are used in 1 out of 3 MRI scans to improve the clarity and quality of images of the body’s internal structures. This helps improve the diagnostic accuracy of MRI scans. GBCAs are used for improved visibility of inflammation, blood vessels, tumors, and for other organs in the body.
Gadolinium (Gd) is found as a rare earth metal, which is tough to extract, and it appears like a silvery white crystal. It is one of the few metals with ferromagnetic properties at room temperature. Like most of the rare earth metals, gadolinium forms trivalent ions with fluorescent properties. Gadolinium is used for shielding in neutron radiography and in nuclear reactor as it absorbs neutrons. Therefore, applications of the metal are seen in oven, microwave, and other electronic components. In medical field, it is utilized merely in the form of solution composites for radiological images enhancement. The gadolinium ions that occur in water soluble salts are toxic to human. But chelated Gd compounds are less toxic to human body as they are filtered out of the kidneys before the free ions get released into the tissue. This property of Gd increases its use in the medical field, where it is used as intravenous drug in diagnostic imaging procedures to enhance the quality of magnetic resonance angiography (MRA) or magnetic resonance imaging (MRI). The global gadolinium-based contrast agent market is a fairly matured market and is expected to witness a significant growth in the near future. The growth of the market is likely to be driven during the forecast period by the rising prevalence of chronic diseases such as cardiac diseases and cancer.
View TOC with Figures and Tables: https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=22862
The global gadolinium-based contrast agent market is segmented on the basis of contrast agent type, disease indication, end-user, and geography. On the basis of contrast agent type, the market is divided into linear non-ionic agent, linear ionic, macrocyclic non-ionic, and macrocyclic ionic. The rates of dissociation of Gd from macrocyclic ligands are slower than the dissociation from linear ligands. Higher the dissociation constant, there is more possibility of de-chelating and release of free Gd ions into the body which may lead to serious adverse events. Therefore, linear gadolinium-based contrast agents are widely preferred for MRI scans.
On the basis of disease indication, the market is segmented into cardiovascular disorders, neurological disorders, respiratory diseases, nephrological disorders, and others. The cardiovascular disorders segment accounted for a large share of the global market and the trend is expected to continue during the forecast period. Advancements in cardiac MRI procedures in catheterization labs and promising reimbursement scenario for contrast agent products used during cardiovascular diagnosis along with highly developed health care infrastructure in countries such as Germany, the U.K., the U.S., and Canada are factors fueling the growth of the cardiovascular disorders segment. According to a survey of the Centers for Disease Control and Prevention, every year about 735,000 people have a heart attack in the U.S. Out of this number, 525,000 are the first heart attacks and 210,000 happen in people who have already suffered a heart attack. In addition, growth of the segment is attributed to the rise in number of diagnostic procedures coupled with the increase in disease burden in developing countries. In terms of end-user, the market is segmented into hospitals, specialty clinics, diagnostic centers, and others.
Geographically, the global gadolinium-based contrast agent market is distributed over North America (the U.S. and Canada), Europe (Germany, France, the U.K., and others), Asia Pacific (Australia, China, Japan, India, and others), Latin America, and Middle East & Africa. North America dominated the market in terms of revenue. North America was followed by Europe and is expected to register a high growth of the market. Emerging markets such as Asia Pacific, Latin America, and Middle East & Africa are expected to record a robust growth during the forecast period owing to growing health care industry and aging population, which consequently are projected to result in the increase of patient population. India, China, and Brazil are likely to drive a significant growth of the market among the emerging countries owing to increase in investments by government bodies in order to enhance health care facilities.
Major players operating in this market are GE Healthcare, Bayer HealthCare, Guerbet, Bracco Diagnostic Inc., and Lantheus Medical Imaging, Inc.